These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2159365)

  • 41. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
    Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
    Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transformation by H-ras can result in aberrant regulation of ornithine decarboxylase gene expression by transforming growth factor-beta(1).
    Hurta RA; Lee J; Voskas D
    J Cell Biochem; 2001; 81(1):39-55. PubMed ID: 11180396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modulation of ras transformation affecting chromatin supraorganization as assessed by image analysis.
    Mello ML; Contente S; Vidal BC; Planding W; Schenck U
    Exp Cell Res; 1995 Oct; 220(2):374-82. PubMed ID: 7556446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
    Mo YY; Beck WT
    Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of expression and function of topoisomerase I and II during meiosis in male mice.
    Cobb J; Reddy RK; Park C; Handel MA
    Mol Reprod Dev; 1997 Apr; 46(4):489-98. PubMed ID: 9094096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
    Baloch Z; Cohen S; Coffman FD
    J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
    Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
    Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
    Chambers AF; Behrend EI; Wilson SM; Denhardt DT
    Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased retinoylation in NIH 3T3 cells transformed with activated Ha-ras.
    Takahashi N; De Luca LM; Breitman TR
    Biochem Biophys Res Commun; 1997 Oct; 239(1):80-4. PubMed ID: 9345273
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells.
    Okura A; Arakawa H; Oka H; Yoshinari T; Monden Y
    Biochem Biophys Res Commun; 1988 Nov; 157(1):183-9. PubMed ID: 2848517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.
    Cunningham JM; Francis GE; Holland MJ; Pirollo KF; Chang EH
    Br J Cancer; 1991 Jan; 63(1):29-36. PubMed ID: 1846552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increment of DNA topoisomerases in chemically and virally transformed cells.
    Crespi MD; Mladovan AG; Baldi A
    Exp Cell Res; 1988 Mar; 175(1):206-15. PubMed ID: 2831071
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of topoisomerase I and II activities in nuclear extracts during callogenesis in immature embryos of Zea mays.
    Carballo M; Giné R; Santos M; Puigdomènech P
    Plant Mol Biol; 1991 Jan; 16(1):59-70. PubMed ID: 1653630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.
    Drake FH; Hofmann GA; Bartus HF; Mattern MR; Crooke ST; Mirabelli CK
    Biochemistry; 1989 Oct; 28(20):8154-60. PubMed ID: 2557897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated gelsolin and alpha-actin expression in a flat revertant R1 of Ha-ras oncogene-transformed NIH/3T3 cells.
    Müllauer L; Fujita H; Suzuki H; Katabami M; Hitomi Y; Ogiso Y; Kuzumaki N
    Biochem Biophys Res Commun; 1990 Sep; 171(2):852-9. PubMed ID: 2169737
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Galectin-3 mRNA level depends on transformation phenotype in ras-transformed NIH 3T3 cells.
    Hébert E; Monsigny M
    Biol Cell; 1994; 81(1):73-6. PubMed ID: 7987244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Image analysis of Feulgen-stained transformed NIH 3T3 cells differing in p21 expression and ras-induced metastatic ability.
    Mello ML; Chambers AF
    Anal Quant Cytol Histol; 1994 Apr; 16(2):113-23. PubMed ID: 8043158
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topoisomerase II: A specific marker for cell proliferation.
    Heck MM; Earnshaw WC
    J Cell Biol; 1986 Dec; 103(6 Pt 2):2569-81. PubMed ID: 3025219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel mechanisms of resistance to inhibitors of DNA topoisomerases.
    Beck WT; Khélifa T; Kusumoto H; Mo YY; Rodgers Q; Wolverton JS; Wang Q
    Adv Enzyme Regul; 1997; 37():17-26. PubMed ID: 9381970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.